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Sonya A. MacParland1,2, Annie Y. Chen1, Christopher P. Corkum1, Tram N.Q. Pham1,3 and Tomasz I. Michalak1*Abstract
Background: Hepatitis C virus (HCV) can replicate in cells of the immune system and productively propagate in
primary T lymphocytes in vitro. We aimed to determine whether exposure to authentic, patient-derived HCV can
modify the proliferation capacity, susceptibility to apoptosis and phenotype of T cells.
Methods: Primary total T cells from a healthy donor were used as targets and plasma-derived HCV from patients
with chronic hepatitis C served as inocula. T cell phenotype was determined prior to and at different time points
after exposure to HCV. T cell proliferation and apoptosis were measured by flow cytometry-based assays.
Results: The HCV inocula that induced the highest intracellular expression of HCV also caused a greatest shift in
the T cell phenotype from predominantly CD4-positive to CD8-positive. This shift was associated with inhibition of
CD4+ but not CD8+ T cell proliferation and did not coincide with altered apoptotic death of either cell subset.
Conclusions: The data obtained imply that exposure to native HCV can have an impact on the relative frequencies
of CD4+ and CD8+ T cells by selectively suppressing CD4+ T lymphocyte proliferation and this may occur in both
the presence and the absence of measurable HCV replication in these cells. If the virus exerts a similar effect in vivo,
it may contribute to the impairment of virus-specific T cell response by altering cooperation between immune cell
subsets.
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expressionIntroduction
Hepatitis C virus (HCV) is a single-stranded RNA virus
that affects 130–150 million people worldwide as a
chronic infection [1]. In HCV-infected patients, viral
replication has been demonstrated not only in hepato-
cytes but also in cells of the immune system, such as B
cells, monocytes, and CD4+ and CD8+ T lymphocytes
[2–6]. In this laboratory, it was uncovered that primary
T lymphocyte cultures, generated by ex vivo treatment
of peripheral blood mononuclear cells (PBMC) from
healthy individuals with a T cell-inducing mitogen phy-
toheamagglutin (PHA), are susceptible to wild-type
(patient-derived) HCV and capable of supporting its* Correspondence: timich@mun.ca
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creativecommons.org/publicdomain/zero/1.0/replication at a level comparable to that of in vivo infected
lymphoid cells [6, 7]. Furthermore, these cells were able to
produce infectious virions that de novo infected lympho-
cytes [7]. It was also uncovered that patient-derived HCV
is significantly more infectious to primary T cells than
laboratory-derived clonal strains of HCV [8]. As well, HCV
infection of T cells requires surface expression of CD5, and
transfection of HCV non-susceptible T cell lines with CD5
renders these cells susceptible to infection [9].
HCV infection causes chronic hepatitis C (CHC) in up
to 85 % of those afflicted, while acute HCV infection is
thought to spontaneously resolve in 15-25 % of cases [1].
Resolution of hepatitis C appears to be a result of a robust
HCV-specific T cell-mediated response. In HCV-infected
chimpanzees, representing the closest animal model of
human HCV infection, recovery from hepatitis C and a
drop in plasma HCV loads to levels undetectable byess article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in any
ly credited. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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cells and CD8+ cytotoxic T cells [10, 11]. In patients with
CHC, T cells display markers of exhaustion and are defect-
ive in their ability to produce interferon-γ (IFN-γ) and
interleukin-2 (IL-2) [12]. In vitro, the functional conse-
quences of T cell infection in Molt-4 and Jurkat T cell
lines and primary T cells have been investigated only using
laboratory-adapted clonal strains of HCV [4, 13, 14]. It
was found, among others, that infection with a HCV SB
strain of Molt-4 cells suppressed IFN-γ signalling through
the STAT-1 pathway [4]. This virus strain was also able to
infect primary CD4+ T cells and this infection was associ-
ated with a decrease in their proliferation [14].
Stemming from the previous observation that infection
of naïve lymphoid cells with patient-derived HCV can
lead to changes in the CD4+ to CD8+ T cell ratio [7], we
asked in the current study whether the virus can differ-
entially alter CD4+ or CD8+ T cell proliferation and/or
their apoptosis resulting in a shift in the T cell pheno-
typic characteristics. We found that the exposure of T
lymphocytes to a naturally occurring HCV, although not
necessarily molecularly evident active virus replication in
these cells, can be sufficient to alter the CD4+ to CD8+
T cell ratio. This phenotypic change was due to the se-
lective inhibition of CD4+ but not CD8+ T lymphocyte
proliferation and was not related to differential apoptotic
death of either T cell subset.
Materials and methods
Plasma-derived HCV inocula and target cells
Plasma from patients C26/F (CHC-1), C33/M (CHC-2),
N28/F (CHC-3) with clinically and serologically docu-
mented CHC served as the source of naturally occurring
HCV. The inocula contained HCV of different genotypes
and viral loads (Table 1). CHC-1 carried a mixture of
genotype 1a and 1b at 1.1 × 106 virus copies, also termed
virus genome equivalents (vge)/mL, CHC-2 had geno-
type 3a at 2 × 104 vge/mL, and CHC-3 carried 2b geno-
type at 2.4 × 106 vge/mL. These HCV plasma donors
had no laboratory evidence of hepatitis B virus (HBV) or
HIV type 1 (HIV-1) infection, as testing of their sera byTable 1 Virological characteristics of individuals with CHC providing
infected with these inocula
Inoculum Case/
Sex
HCV
genotype
Plasma HCV
RNAa (vge/mL)
HCV RNA load in ce
1 d.p.i.
Positive stranda
(vge/μg RNA)
CHC-1 C26/F 1a/1b 1.1 × 106 8777
CHC-2 C33/M 3a 2 × 104 746
CHC-3 N28/F 2b 2.4 × 106 <50
dpi days post-infection, F female, M male, NT not tested, pos positive, neg negative
aQuantified by in house real-time RT-PCR
bDetermined by the strand-specific RT-PCR/NAHstandard clinical assays indicated, and clinically apparent
chronic morbidity other than CHC.
Lymphoid cells serving as targets for in vitro HCV in-
fection experiments were isolated from a single healthy
donor who had no clinical history or molecular indica-
tion of HCV exposure, as confirmed by testing for anti-
bodies to HCV (anti-HCV) and examining serum and
PBMC by highly sensitive HCV-specific RT-PCR/nucleic
acid hybridization (NAH) assay (sensitivity of <10 vge/
mL or <2.5 IU/mL) [2]. The donor was also serum HBV
DNA and HIV-1 RNA nonreactive and had normal ala-
nine aminotransferase (ALT) level, as determined by
conventional clinical assays.
In vitro HCV infection
De novo infection of lymphoid cells with HCV was car-
ried out following the method reported before, including
monocyte depletion to enhance viral replication in lym-
phocytes [7]. Briefly, monocyte depletion was carried out
by plastic adherence for 4 h. This led to a three-fold de-
crease in CD14+ monocytes, as measured by flow cy-
tometry (Additional file 1: Figure S1). Previously, we
have shown that intermittent stimulation of PBMC ex-
posed to HCV ex vivo with phytohemagglutinin (PHA)
in the presence of human recombinant interleukin-2
(IL-2) leads to HCV propagation [7]. However, these
conditions also augmented lymphocyte proliferation and
led to a relatively high rate of lymphocyte apoptosis
(data not shown). These outcomes were likely related to
the repeated stimulation with PHA. To minimize this ef-
fect, which potentially masked the influence of HCV on
cell proliferation and apoptosis, we stimulated lymphoid
cells with PHA only once prior to infection in the
current study. Thus, monocyte-depleted lymphoid cells
from a healthy donor were treated with 5 μg/mL PHA
(Sigma-Aldrich, Mississauga, Ontario, Canada) for 48 h
[7]. Following stimulation, 1 × 107 cells were exposed to
2.7 × 105 vge from CHC-1 or CHC-3 or to 500 μL (1 × 104
vge) of plasma from CHC-2 in 9.5 mL of culture medium.
In addition, the same number of target cells was exposed
to three 500-μL samples of normal healthy plasma (NHP)plasma serving as HCV inocula and HCV RNA loads in T cells
lls
7 d.p.i. 10 d.p.i.
Negative
strandb
Positive stranda
(vge/μg RNA)
Negative
strandb
Positive stranda
(vge/μg RNA)
Negative
strandb
neg 1290 pos 1010 pos
neg 204 neg neg NT
NT <50 NT <50 NT
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other control, target cells were cultured with 9.5 mL of
medium alone (NP, no plasma). In all cases, inocula or
NHP were removed after 24 h and the cells washed thor-
oughly prior to suspension in 9.5 mL of medium, as de-
scribed [7]. Cells were cryopreserved for analysis prior to
and after PHA stimulation (time 0) and at 1, 4, 7 and 10
d.p.i., unless otherwise indicated. In addition, cells were
collected at each of the above time points to determine
cell phenotype and apoptosis (see below).
Inhibition of HCV infection in T lymphocytes by Telaprevir
Telaprevir (TLP or VX-950), an HCV NS3-4A protease
inhibitor, was purchased from Vertex Pharmaceuticals
(Cambridge, Massachusetts, USA). TLP had shown cap-
ability of complete inhibition of HCV replication in de
novo infected Molt4 T cell line [9] and naturally HCV-
infected PBMC (Chen et al., manuscript submitted). At
concentrations equal to or below 4 μM, TLP is not toxic
to human lymphocytes, as assessed before [9]. We ap-
plied the previously established treatment conditions
with TLP to determine whether the shift in CD4+ T cell
proliferation can be normalized in the absence of detect-
able virus replication in the cells previously exposed to
HCV. Briefly, approximately 5 × 106 cells were incubated
in duplicate with CHC-1 or CHC-2 plasma under condi-
tions described above in the presence or absence of
4 μM TLP in 0.5 % DMSO. The cells were harvested
after 10 d.p.i. for evaluation of expression of HCV RNA
positive and negative strands, as described above, and
the CD4 and CD8 T cell frequency determined by flow
cytometry. In parallel, lymphocytes exposed to the same
amounts of CHC-1 or CHC-2 HCV alone and those in-
cubated in culture medium supplemented with NHP in
the absence of TLP served as infection controls.
HCV RNA positive and negative strand detection
HCV RNA positive strand in de novo infected lymphoid
cells as well as in patients’ plasma was determined by
HCV-specific real-time RT-PCR (sensitivity 100 vge/mL)
[2]. Expression of HCV RNA negative strand in T cells
was detected by strand-specific RT-PCR/NAH using rTth
DNA polymerase as described before (sensitivity ~100
copies/μg total RNA) [2, 9].
Determination of cell phenotype
Phenotype of the cells exposed to HCV inocula, NHP or
cultured in medium alone was assessed by incubation of
1 × 105 cells per reaction with a cocktail containing an
anti-CD3 monoclonal antibody (mAb) conjugated with
Alexa Flour 488 (Alexa 488) (BD Pharmingen, San Diego,
California, USA), an anti-CD4 mAb labelled with peridi-
nin chlorophyll protein complex (PerCP) (BD Pharmin-
gen) and an anti-CD8 mAb conjugated to allophycocyanin(APC) (Ebiosciences, San Diego, California, USA), an anti-
CD14 mAb labeled with phycoerythrin (PE) (Ebiosciences)
or with a control cocktail of the appropriate isotype mAb
controls (Ebiosciences or BD Pharmingen) for 30 min at
4 °C. Using forward versus side scatter, lymphocytes were
separated from debris by flow cytometric analysis (gate
R1; see Fig. 1b). Then, lymphocytes were sub-gated on
Alexa-488-positive CD3+ T cells (gate R2; see Fig. 1b) to
enumerate in the next step APC-positive CD8+ cells lo-
cated in the lower right (LR) quadrant and PerCP-positive
CD4+ cells located in the upper left (UL) quadrant (see
Fig. 1b). Quadrant markers were set up on background
staining with appropriate isotype controls.Flow cytometry-based T cell proliferation assay
To quantify proliferation of lymphocytes exposed to
HCV or NHP, cells were stained with carboxyfluorescein
succinimidyl ester (CFSE), as previously reported [15].
Briefly, ~2 × 107cells were incubated with CFSE (Mo-
lecular Probes, Eugene, Oregon, USA) at the pre-tested
nontoxic concentration of 1 mM for 10 min at 37 °C
and washed twice with 10 mL of 5 % fetal calf serum
(FCS; GIBCO-Invitrogen Corporation, Auckland, New
Zealand). To carry out triplicate infection with each of
the HCV inocula tested, NHP or NP control, CFSE-
labelled lymphocytes were suspended at 1 × 106 cells in
one mL of medium containing 10 % FCS in 6-well
plates. As an additional control, CFSE-labelled cells in
medium alone were included. Cell proliferation was
measured in triplicate wells before stimulation with
PHA and at 0, 1, 4, 7 and 10 d.p.i., unless otherwise
stated. The data were analyzed with Cellquest Pro
(Becton Dickinson, San Jose, California, USA) or ModFit
LT (Verity Software House, Topsham, Main, USA) soft-
ware. Using forward versus side scatter, lymphocytes
(gate R1) were separated from debris. Proliferation was
presented as the mean percentage of CFSE-low cells
with standard error of mean (SEM) from triplicate cul-
tures using percentage of CFSE-low cells from cultures
maintained in medium alone as the baseline. In the pro-
liferation experiments, CFSE-labelled lymphoid cells
were additionally stained with a cocktail of APC-anti-
CD3, PerCP-anti-CD4 and PE-anti-CD8 mAbs, as
outlined above. Using forward versus side scatter, lym-
phocytes were separated from debris, gated on CD3+ T
cells, and sub-gated on CD4+ or CD8+ T cells to deter-
mine the proliferation of individual T cell subsets. Mito-
gen non-stimulated controls were routinely included, as
described above. Dilution of CFSE fluorescence in the
cells was measured using the proliferation wizard mod-
ule of ModFit LT software revealing daughter cell gener-
ations. Proliferation index (P.I.) was determined using
non-stimulated cells to define the parent generation.
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Fig. 1 Phenotypic characterization of cultured lymphocytes after exposure to HCV. Lymphoid cells from the same healthy donor were either
exposed to medium alone (no plasma, NP), normal human plasma (NHP 1–3) or HCV inocula (CHC 1–3). Cells collected at the time points
indicated (d.p.i.) were stained for CD3, CD4 and CD8 or with isotype controls and analysed by flow cytometry. a Graphical representation of flow
cytometry data showing phenotype of T cells for each infection condition tested. CD4+ T cells (solid black bars) and CD8+ T cells (hatched bars)
are displayed as percentage of total CD3+ T cells at 4 different time points. The detection of HCV RNA positive strand was shown for 1, 7 and 10
d.p.i. For HCV RNA positive strand detection, (+++) indicates >5,000 vge/μg RNA, (++) between 500 and 5,000 vge/μg RNA, (+) between 50 and
500 vge/μg RNA, and (+/−) below 50 vge/μg RNA. For negative strand detection, (+) indicates detection and (−) no detection of the strand.
Boxes indicate cultures in which the CD4+ to CD8+ ratio was altered when compared to cultures exposed to NP or NHP. n.a.- not applicable, n.
t.- not tested. b Determination of T cell phenotype in cell cultures exposed or not to HCV and cultured for 10 d.p.i. Using forward versus side
scatter, lymphocytes (gate R1) were separated from cellular debris. Lymphocytes were sub-gated on Alexa-488-positive CD3 T cells (gate R2) for
enumeration of CD4+ and CD8+ T cells by detecting APC-positive CD8+ T cells found in the lower right (LR) quadrant and PerCP-positive CD4+ T
cells in the upper left (UL) quadrant. Numbers in the UL and LR quadrants indicate percentages of positive cells
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To determine the degree of apoptosis after exposure
to HCV inocula or NHP, cells were stained with
annexin V conjugated with phycoerythrin (PE), or 7-
aminoactinomycin D (7-AAD), as previously established
[16]. Briefly, 1 × 105 cells were washed with annexin buffer
containing 10 mM HEPES (Invitrogen), 5 mM NaCl,
5 mM KCl and 2 mM CaCl2 and centrifuged at 1,500 rpm
for 10 min at 4 °C. Then, a cocktail containing 50 μg/mL
of 7-AAD (Invitrogen) and 50 μg/mL of annexin-V-PE
(Invitrogen) were prepared in annexin buffer. Cells were
suspended in 100 μL of apoptosis cocktail and kept on ice
for 30 min. After staining, cells were washed once with
annexin buffer, spun down and suspended in 500 μL of
annexin buffer to be analyzed by flow cytometry [16].
Quantification of cytokine expression
In cultures in which numbers of recovered cells permitted,
RNA was extracted, treated with DNase [17] and reversely
transcribed [2]. Due to very limited numbers of cells avail-
able for RNA extraction, quantification of expression was
feasible only for IFN-γ, IFN5-α (IFN-5α), tumor necrosis
factor-α (TNF-α), and IL-2. This was done using cDNA
(50 ng RNA equivalent) and amplification conditions pre-
viously reported [17]. Amplification reactions were
performed using the following primers: sense primer 5′-
TCAGCTCTGCATCGTTTTGG and antisense primer
5′-TGTTTTAGCTGCTGGGCACA for IFN-γ, sense pri-
mer 5′-CAGCCTGAGTAACAGGAGGA and antisense
primer 5′-GCAGATGAGTCCTTTGTGCT for IFN-5α,
sense primer 5′-TCTTCTCGAACCCCGAGTGA and
antisense primer 5′-CCTCTGATGGCACCACCAG for
TNF-α, and sense primer 5′-CCCAAGAAGGCCACAGA
ACT and antisense primer 5′-TGCTGATTAAGTCCCT
GGGTCTTA for IL-2. Expression of the genes was nor-
malized to β-actin.
Statistical analysis
Data were analyzed and differences between HCV-
exposed cultures and those not exposed to virus were
determined using GraphPad Prism 4 software (GraphPad
Software Inc., San Diego, California, USA). Statistical
significance was evaluated by two-tailed Mann–Whitney
test. P values equal to or lower than 0.05 were consid-
ered as significant.
Results
HCV expression in de novo infected lymphoid cells
HCV RNA positive strand was detected in T cell cultures
following exposure to all three inocula tested (Table 1),
but not in those exposed to NHP or medium alone (Fig. 1).
The level of HCV RNA detection varied depending on in-
oculum and time of cell collection. HCV RNA load ranged
from <50 to 8.7 × 103 vge/μg total RNA (Table 1). HCVRNA negative (replicative) strand was detected at 7 and
10 d.p.i. in cultures exposed to CHC-1 inoculum that also
gave the highest level of HCV RNA positive strand expres-
sion among the inocula tested.
T cell phenotype after exposure to HCV
In preliminary experiments and in the study previously
reported [7], cells exposed to HCV were maintained in
culture in the presence of IL-2 under alternating stimu-
lation with PHA. After 14 days of culture, more than
98 % cells were CD3-reactive and CD8+ T cells were evi-
dently more prevalent than CD4+ T cells in cultures ex-
posed to HCV [7]. Similarly, the current study, exposure
of normal lymphoid cells to 2 of 3 HCV inocula tested,
i.e., CHC-1 and CHC-2, resulted in a change in the CD4+
to CD8+ T cell ratio in that CD8+ T cells became more
prevalent compared to cultures exposed to NHP or cul-
tured in medium alone (Fig. 1). Figure 1a shows relations
between numbers of the CD4+ and CD8+ T cells in cul-
tures exposed to HCV, NHP or medium alone during the
10-d.p.i. investigation period. Thus, at 1 d.p.i. the ratio of
CD4+ T to CD8+ T cells was approximately 4.4 to 1 (with
CD8+ T cells taken as 1) and was not noticeably influ-
enced by whether the cultures were exposed or not to
HCV. At 4 d.p.i., the ratio of CD4+ to CD8+ T cells chan-
ged on average to 1.2 to 1, with the exception of culture
exposed to CHC-1 inoculum in which CD8+ T cells were
enriched and the CD4+ to CD8+ ratio shifted to 0.6 to 1.
At 7 d.p.i., a change in the T cell subset distribution was
also observed for cells inoculated with CHC-2. At this
time point, the CD4+ to CD8+ T cell ratio for CHC-1 was
0.6 to 1 and for CHC-2 1.1 to 1, while for CHC-3, NHP-1,
NHP-2, NHP-3 and NP the ratio was close to 1.5 to 1. At
10 d.p.i., the CD4+ to CD8+ ratio for T cells exposed to
CHC-1 and CHC-2 were 1.3 to 1 and 1.2 to 1, respect-
ively, while the control cultures and that exposed to CHC-
3 had CD4+ to CD8+ ratios of approximately 3.5 to 1
(Fig. 1a). Thus, in contrast to CHC-1 and CHC-2, CHC-3
inoculum had no effect on T cell subset phenotype and
behaved, in this regard, as control NHP. This inoculum
induced a very low, unquantifiable level of HCV RNA in
lymphocytes throughout the culture period (Table 1 and
Fig. 1a), which may suggest very limited uptake of the
virus carried in this inoculum by PBMC. Taken together,
these findings suggested that a change in T cell subset dis-
tribution could be related to the cellular level of HCV
RNA expression.
Apoptosis of lymphoid cells following exposure to HCV
To determine whether the observed enrichment in CD8+
T cells after exposure to HCV was due to enhanced apop-
tosis of CD4+ T cells, the degree of lymphoid cell death
was determined in triplicate cultures after exposure to a
given HCV inoculum or NHP. As shown in Fig. 2, at the
AB
Fig. 2 Quantification of lymphoid cell apoptosis by annexin-PE/7-AAD flow cytometry assay. a Graphical representation of degree of apoptosis
detected in PHA-treated lymphoid cell cultures and exposed to NP, NHP 1–3 or CHC 1–3. Bars indicate the percentage of total cells in each phase of
apoptosis. Graphs present data from triplicate experiments and are shown as mean ± SEM at 1, 4, 7 and 10 d.p.i. Bars with diagonal lines represent
viable cells, checkered bars, early apoptotic cells, bars with horizontal lines, late apoptotic cells and vertical lines, necrotic cells. b Flow cytometric
determination of stage of apoptosis and percentage of T cells in cultures exposed to NP, NHP or HCV at 10 d.p.i. after staining with annexin-PE and
7-AAD. Each quadrant represents a different phase of apoptosis: lower left (LL), viable cells; lower right (LR), early apoptotic cells; upper right (UR), late
apoptotic cells and upper left (UL), necrotic cells. Numbers indicate percentages of cells in each quadrant
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proximately similar and not noticeably related to whether
the cells were cultured in the presence of medium alone,
NHP or HCV (Fig. 2a and b). Thus, under the conditions
tested, the virus did not increase the rate of T cell apop-
totic death. To assess whether the alteration in phenotype
may result from selective apoptosis of CD4+ or CD8+ T
cells, the extent of apoptotic death of these two subsets
was examined separately. We found that exposure to
HCV did not differentially alter apoptosis of these cells
(data not shown).
T cell proliferation after exposure to HCV
To determine the rate of T cell proliferation after expos-
ure to HCV or NHP, triplicate cell cultures were evalu-
ated using the flow cytometry-based CFSE proliferation
assay. In preliminary experiments, T cells which had
been stimulated more than once with PHA proliferated
rapidly irrespective of HCV exposure (data not shown).
However, in the current study, where cells were acti-
vated only once with mitogen prior to HCV exposure,
the infection resulted in significant (P = 0.03) inhibition
of proliferation in the total T cell population (Fig. 3a and
Additional file 2: Figure S2). Upon further examination,
it was established that CHC-1 and CHC-2 inocula inhib-
ited T cell proliferation, while CHC-3 as well as NHP1-3
did not exert any remarkable anti-proliferative effect
(Fig. 3b and Additional file 2: Figure S2).
Proliferation of T cell subsets in cultures exposed to HCV
To evaluate whether the observed inhibition in prolifera-
tion of the total T cell population could be limited to a
particular T cell subset, the proliferation rates of CD4+
and CD8+ T cells were measured. When comparing cul-
tures exposed to HCV to those treated with NHP, a30
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observed in earlier experiments, HCV-exposed PBMC
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Interestingly, TPL treatment did not impact the relative
decrease in the CD4+ T cell frequency caused by expos-
ure to CHC-1 and CHC-2 inocula (Fig. 5). This suggests
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Fig. 4 CD4+ and CD8+ T cell proliferation rates after exposure to HCV. Lymphoid cells from the same healthy donor were stained with CFSE, PHA-
stimulated and infected as described in Materials and Methods to measure proliferation of CD4+ and CD8+ T cell subsets. a Graphical representation of
proliferation of T cell subsets after exposure to either NHP or HCV inocula. Proliferation represented by the mean percentage CFSE low ± SEM was
measured at 4, 7 and 10 d.p.i. b The rates of T cell subset proliferation in cultures exposed to individual HCV inocula or NHP. Proliferation is represented
by the mean percentage CFSE-low ± SEM measured at 3 different time points during the 10-d.p.i. culture
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To recognize the effects of HCV on the T cell cytokine
expression, levels of IFN-γ, TNF-α, IFN-α5 and IL-2
mRNA were quantified in the cells treated with HCV in-
ocula or control NHP. Due to very limited amounts of
RNA, evaluation of these 4 cytokines in all cell cultures
at different time points was not always feasible. In cells
stimulated with PHA for 48 h prior to infection, there
was an evident upregulation in IFN-γ transcription (data
not shown). After PHA stimulation, IFN-γ induction
achieved a peak at 1 d.p.i. in cultures exposed to 2 of 3
NHP and to all 3 HCV inocula tested. Then, the cyto-
kine expression declined in the cultures treated with
HCV but not in those exposed to NHP. Nonetheless,
differences in the IFN-γ mRNA level between the cul-
tures exposed or not to HCV did not achieve statistical
significance at any of the time points examined. For
TNF-α, the cytokine expression sharply declined toundetectable level at 1 d.p.i. in cultures exposed to
CHC-1 and CHC-2, but not in those exposed to NHP
1–3 or CHC-3 inoculum. It is of note that cultures
which lost temporarily TNF-α transcription were those
in which the highest levels of cellular HCV RNA were
detected (Table 1). Further, IFN-α5 expression was not
detected in cells either exposed to HCV or NHP. In re-
gard to IL-2, the cytokine mRNA level tended to be up-
regulated at 1 d.p.i. in cultures exposed to NHP-1 and
NHP-2, but not in those treated with HCV. At later time
points, IL-2 transcription level progressively declined in
cultures exposed to HCV inocula but not in those
treated with NHP, although the difference was statisti-
cally insignificant at the end of follow-up (10 d.p.i.).
Discussion
In this study, we examined the effect of authentic HCV
on the proliferative capacity, apoptosis and phenotype of
Fig. 5 Phenotypic characterization of lymphocytes after exposure to HCV in the presence or absence of TLP. Lymphoid cells from a healthy
donor were exposed in duplicate to CHC-1 or CHC-2 or to normal healthy human in the absence (untreated) or presence of TLP (TLP treated).
Cells were collected at 10 d.p.i., stained for CD3, CD4 and CD8 or with isotype controls, and analyzed by flow cytometry. Percentage CD4+ T cell
decrease and percentage CD8+ T cell increase was calculated based on CD4+ and CD8+ T cell frequencies (taken as 100 %) in control cultures
exposed to normal human plasma
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oid cells to 2 of 3 HCV inocula caused a decrease in the
frequency of CD4+ T cells compared to virus-untreated
cultures with a relative increase in CD8+ T cells. This
relative CD8+ T cell enrichment was a result of a signifi-
cant reduction in CD4+ T cell proliferation compared to
the cultures exposed to normal healthy plasma. On this
note, the effect appeared to correlate with HCV cell up-
take, since the shift in the CD4+ to CD8+ ratio was high-
est in the cultures in which virus exposure lead to
quantifiable levels of HCV RNA positive strands and, in
the case of CHC-1, negative strands in test cells
(Table 1). This was consistent with the observation that
in cultures exposed to CHC-1 inoculum, which induced
the highest levels of HCV RNA positive strand and de-
tectable HCV RNA negative strand, the inhibition in
CD4+ T cell proliferation appeared earlier, i.e., 4 d.p.i.
In the cells exposed to CHC-2 inoculum, T cell prolif-
erative and phenotypic changes were seen in the ab-
sence of detectable HCV replicative intermediate and
after 10-fold lower multiplicity of infection compared
to cells exposed to CHC-1. In the case of CHC-3, while
the plasma viral load was higher than CHC-2 and com-
parable to CHC-1, there did not appear to be much
virus uptake by cells, as indicated by undetectable
HCV RNA by our high sensitivity assays. This may
suggest that the amount of virus taken by cells exposed
to CHC-3 was minuscule. HCV genotype may also play
a role in the anti-proliferative effects observed, as
CHC-1 carried an HCV genotype 1a/1b mix, CHC-2
genotype 3a, and CHC-3 genotype 2b. It is of note that
there was no impact of TLP treatment on the change
in the CD4+ and CD8+ T cell frequency, which sug-
gests that exposure to HCV and uptake of the virus bycells rather than replication itself may be driving these
phenotypic changes (Fig. 5).
Previously, infection of T cell lines and primary T cells
with laboratory-derived HCV clones led to the impairment
of T cell proliferation and IFN-γ production [4, 14]. In the
current study, we show an anti-proliferative effect using
patient-derived HCV as a virus source. The biological im-
pact of HCV lymphotropism on immune cell function is a
topic that is still not well understood. However, it was
shown that HCV infection can led to disruption of im-
munological activity of different types of immune cells, in-
cluding T cells, B cells, dendritic cells, monocytes and
macrophages [4, 14, 18, 19].
In cultures exposed to CHC-3 inoculum, the level of
HCV RNA positive strand detected during the 10-d.p.i.
culture period was unquantifiable by a real time RT-PCR
assay (below 50 vge/μg total RNA). However, HCV RNA
signals were detected, as confirmed by NAH analysis of
amplicons produced by real-time RT-PCR (data not
shown). In this situation, detection of virus RNA nega-
tive strand would not be feasible, and, therefore, was
not attempted (Table 1). As indicated, CHC-3 inoculum
did not induce changes in T cell proliferation or pheno-
type, similarly as NHP-1-3, suggesting that regardless
of the viral load in the inocula, if the virus cannot be
taken up by cells, then the cells’ proliferation is not
affected. We have previously shown that not all
patient-derived HCV inocula are infectious to ex vivo
pre-stimulated lymphoid cells [7, 20]. The viral and
host factors determining infectivity of T cells by wild-
type HCV have yet to be recognized and are under in-
vestigation in this laboratory [8, 9, 21].
In experiments leading to this study, alternating stimu-
lation with PHA and IL-2 was applied to upregulate
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augment virus replication [7]. In the current work,
repeated stimulation with PHA after the initial 48-h treat-
ment was not employed to prevent excessive cell activa-
tion that may mask virus pro- or anti-proliferative or
apoptotic effects. The removal of this periodical stimula-
tion resulted in a decreased HCV replication and, there-
fore, a reduced detection of both virus RNA positive and
negative strands. This finding is consistent with previous
observations in regard to HCV replication in lymphoid
cell cultures [22] and in in vitro infections with other vi-
ruses [23–25].
It is well recognized that HCV-specific CD4+ T cell re-
sponse in individuals chronically infected with HCV is
poor or absent [26]. In HCV-infected patients who tran-
siently control viremia and have fluctuating plasma viral
load, including periods of apparent HCV RNA negativ-
ity, this transient viral control is accompanied by in-
creased virus-specific CD4+ T cell response [26]. In
patients with CHC, T cells have been found to be im-
paired in the production of IFN-γ and IL-2 [12]. As well,
studies investigating CD4+ T cell function during a
symptomatic persistent HCV infection have shown a sig-
nificant loss of IL-2 secreting cells compared to individ-
uals who spontaneously resolved viremia, as well as a
weak IFN-γ production by HCV-specific CD4+ T cells
upon stimulation [27]. In the latter study, HCV-specific
IFN-γ production by CD4+ T cells was rescued after
in vitro culture with exogenous IL-2, but the effect of
IL-2 on the CD4+ T cell proliferation was not measured.
These findings may suggest that impaired proliferation
of CD4+ T cells observed in our study could be due to
weakened IL-2 production. However, only CD4+ T cells
but not CD8+ T cells were affected. Due to limitations
in cell numbers we were not able to evaluate whether
there was indeed impaired IL-2 and/or IFN-γ cytokine
production by in vitro infected T cells. This issue re-
quires further investigation. Preliminary data obtained in
this regard in the present study indicate that there were
no significant differences between T cells exposed or not
to HCV in terms of IFN-γ, IFN-5α and IL-2 mRNA ex-
pression. However, TNF-α transcription appeared to be
transiently but severely down-regulated shortly (i.e., 1
d.p.i.) after exposure to CHC-1 or CHC-2. This finding
warrants further examination. Nonetheless, it needs to
be taken under consideration that the level of cytokine
gene expression may not accurately reflect the cytokine
protein production.
The results of this study should be interpreted with
certain limitations taking under consideration that
PBMC exposed to authentic HCV were isolated from a
single healthy donor. The observations made might be
limited to this particular donor and experiments with
cells from other healthy individuals are needed toconfirm the findings. However, we have previously re-
ported that a comparable shift in the CD4+ to CD8+ T
cell ratio also occurred after exposure to native HCV of
T cells from another healthy donor [7].
Overall, our findings imply that exposure to HCV can
modify the T cell phenotype due to a relative decrease in
the proliferation capacity of CD4+ T cells. Furthermore,
exposure to naturally occurring HCV in vitro did not ap-
pear to differentially augment apoptotic death of lympho-
cyte subsets, although apoptotic effects of a HCV clone on
T cells have been described previously [18]. In this con-
text, it needs to be determined whether primary CD4+
and CD8+ T cells derived from patients with CHC display
similar characteristics. The results from the current study
raise a possibility that HCV may exert a direct effect on
the overall T cell phenotypic properties and, in conse-
quence, on the function of T cells as a whole in HCV-
infected patients.
Additional files
Additional file 1: Figure S1. Monocyte depletion prior to cell infection
with HCV. Monocytes were depleted from PBMC via plastic adherence for
4 h and their frequencies in total PBMC and monocyte-depleted PBMC
were determined after staining with anti-CD14 antibody by flow
cytometry.
Additional file 2: Figure S2. Flow cytometric determination of T cell
proliferation after exposure to medium alone (NP), NHP 1–3 or HCV
inocula CHC 1–3 at 7 d.p.i. Using forward versus side scatter, lymphocytes
(gate R1) were separated from debris. Percentage CFSE low was
determined based on unstimulated control cells cultured with medium
alone. Low left (LL) and low right (LR) quadrants represent cells with
CFSE low (dim) and CFSE high (bright) reactivity, respectively. Dilution of
CFSE fluorescence was analyzed with ModFit LT showing daughter
generations. P.I. values were determined by using non-stimulated cells to
define parent generation.
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